Verastem says VS — 7375 posts 50% confirmed ORR in second — line KRAS G12D pancreatic cancer trial
Verastem disclosed early trial results for its oral KRAS G12D inhibitor VS-7375, showing tumor shrinkage across several advanced cancers. Data were presented as an initial multi-tumor clinical update from the ongoing TARGET-D 101 Phase 1/2 study. Pancreatic cancer readout showed deep, durable responses, supporting 900